Weekly chemotherapy instead of best supportive care alone must be considered for patients of small cell lung cancer with poor performance status.

被引：0
|
作者：
Shrivastav, Gunjan
Gupta, Alok
Sonthwal, Neha
Singla, Suhas Kirti
Mohindra, Tarun
Chaturvedi, Harit Kumar
Rohatgi, Nitesh
机构：
[1] Max Inst Canc Care, Delhi, India
[2] Medanta Mediclin, Lucknow, Uttar Pradesh, India
[3] Max Super Specialty Hosp, Max Inst Canc Care, New Delhi, India
[4] Max Healthcare, New Delhi, India
[5] Max Oncol Daycare Ctr, Delhi, India
[6] Max Superspecialty Hosp, New Delhi, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21102
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prognosis of patients with recurrent nonsmall cell lung cancer who received the best supportive care alone
    Sonoda, Dai
    Kondo, Yasuto
    Maruyama, Raito
    Naito, Masahito
    Mikubo, Masashi
    Shiomi, Kazu
    Satoh, Yukitoshi
    CURRENT PROBLEMS IN SURGERY, 2024, 61 (01)
  • [22] Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
    Lee, Keun-Wook
    Lim, Joo Han
    Kim, Jee Hyun
    Lee, Choon-Taek
    Lee, Jong Seok
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2008, 23 (06) : 992 - 998
  • [23] Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non-Small Cell Lung Cancer in Jordan
    Al Rabayah, Abeer
    Al Froukh, Rawan
    Sawalha, Razan
    Al Shnekat, Maali
    Jahn, Beate
    Siebert, Uwe
    Jaddoua, Saad M.
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 43
  • [24] Outcome of treatment in patients with small cell lung cancer in poor performance status
    Bahij, Rana
    Jeppesen, Stefan Starup
    Olsen, Karen Ege
    Halekoh, Ulrich
    Holmskov, Karin
    Hansen, Olfred
    ACTA ONCOLOGICA, 2019, 58 (11) : 1612 - 1617
  • [25] AUDIT OF LUNG CANCER CHEMOTHERAPY FOR PATIENTS OF POOR PERFORMANCE STATUS
    Taylor, Henry
    Shah, Riyaz
    Sevitt, Tim
    Cominos, Matilda
    Burcombe, Russell
    Beesley, Sharon
    Visioli, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1307 - S1307
  • [26] COST-UTILITY OF CHEMOTHERAPY AND BEST SUPPORTIVE CARE IN NON-SMALL-CELL LUNG-CANCER
    KENNEDY, W
    REINHARZ, D
    TESSIER, G
    CONTANDRIOPOULOS, AP
    TRABUT, I
    CHAMPAGNE, F
    AYOUB, J
    PHARMACOECONOMICS, 1995, 8 (04) : 316 - 323
  • [27] Prognosis of stage I non-small cell lung cancer patients aged ≥ 80 years who were considered medically operable but received best supportive care alone
    Kashiwabara, Kosuke
    Fujii, Shinji
    Tsumura, Shinsuke
    Sakamoto, Kazuhiko
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
  • [28] COMPARISON OF ALTERNATE-DAY ADMINISTRATION OF GEFITINIB AND BEST SUPPORTIVE CARE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER IN PATIENTS WITH POOR PERFORMANCE STATUS: DATA FROM A RETROSPECTIVE STUDY
    Kasamatsu, Y.
    Yoshinoya, K.
    Kadoya, M.
    Kasamatsu, Y.
    RESPIROLOGY, 2011, 16 : 184 - 184
  • [29] Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer
    Medley, L
    Cullen, M
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (04) : 384 - 388
  • [30] Chemotherapy versus best supportive care for advanced nonsmall-cell lung cancer
    Abang, AM
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (24) : 2980 - 2984
12345